{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:17:25Z","timestamp":1785417445509,"version":"3.56.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Paronychia is a common toxicity associated with targeted anticancer therapies. Antibiotics and steroids are the standard treatments for severe paronychia, yet they are often inadequate, prolonging the patient's suffering and resulting in changes to effective cancer therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>This article describes the clinical course of drug-induced paronychia and attempts to identify circumstances under which nail surgery may be beneficial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>This is a retrospective case series from a single institution's electronic medical record for patients on paronychia-inducing anticancer therapies with nail disease visit diagnosis codes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The authors identified 36 nail procedures performed on 12 patients, all of whom were managed with conservative steroid and antibiotic therapy with varying degrees of improvement; however, no further improvement was seen after 90 days. Partial matricectomy, nail avulsion, debridement\/clipping, and incision and drainage were performed with resolution rates of 100% (11\/11), 38.5% (5\/13), 12.5% (1\/8), and 0% (0\/4), respectively. The average time to surgical intervention was 196 days, and the average time to resolution was 268 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>This series highlights the prolonged course of severe drug-induced paronychia and the importance of surgical intervention to reduce pain and impact on cancer treatment. Partial matricectomy should be considered for paronychia unresponsive to conservative therapy by 3 months.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003036","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T14:02:37Z","timestamp":1621864957000},"page":"775-779","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies"],"prefix":"10.1097","volume":"47","author":[{"given":"Hannah L.","family":"Hanania","sequence":"first","affiliation":[{"name":"Department of Dermatology, the University of Texas MD Anderson Cancer Center, Houston, Texas;"},{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Pacha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Heberton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the University of Texas MD Anderson Cancer Center, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250731","first-page":"44","article-title":"Acute and chronic paronychia","volume":"96","author":"Leggit","year":"2017","journal-title":"Am Fam Physician"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1684\/ejd.2016.2747","article-title":"Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma","volume":"26","author":"Dika","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"Suppl 1","key":"R3-20250731","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/idoj.IDOJ_133_18","article-title":"Systemic drug-induced chronic paronychia and periungual pyogenic granuloma","volume":"9","author":"Wollina","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3747\/co.22.2430","article-title":"Management of egfr tki-induced dermatologic adverse events","volume":"22","author":"Melosky","year":"2015","journal-title":"Curr Oncol"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1346-8138.13205","article-title":"Effective treatments for paronychia caused by oncology pharmacotherapy","volume":"43","author":"Goto","year":"2016","journal-title":"J Dermatol"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00280-019-03970-8","article-title":"Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab","volume":"85","author":"Mortimer","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000452425","article-title":"Development of photoonycholysis with vandetanib therapy","volume":"2","author":"Negulescu","year":"2017","journal-title":"Skin Appendage Disord"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdcr.2018.03.005","article-title":"Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition","volume":"5","author":"Dewan","year":"2019","journal-title":"JAAD Case Rep"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1684\/ejd.2013.2048","article-title":"The impact of nail disorders on quality of life","volume":"23","author":"Belyayeva","year":"2013","journal-title":"Eur J Dermatol"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","article-title":"EGFR inhibitors and cutaneous complications: a practical approach to management","volume":"5","author":"Guggina","year":"2017","journal-title":"Oncol Ther"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/0019-5154.123482","article-title":"Management of chronic paronychia","volume":"59","author":"Relhan","year":"2014","journal-title":"Indian J Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:14:19Z","timestamp":1754000059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003036","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}